Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 3/20 | 1.00 |
| ▸ | TRPC3 | Q13507 | 3/20 | 1.00 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 1.00 |
| ▸ | CRACR2A | Q9BSW2 | 9/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.56 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7320623 | 0.91 | ORAI1 (0.83) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL12637675 | 0.91 | ORAI1 (0.83) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL7314655 | 0.90 | ORAI1 (0.81) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL7325953 | 0.89 | ORAI1 (0.80) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL20301709 | 0.88 | ORAI1 (0.78) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL7326566 | 0.87 | ORAI1 (0.77) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL7319488 | 0.87 | ORAI1 (0.77) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL7319119 | 0.86 | ORAI1 (0.75) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL7315476 | 0.86 | ORAI1 (0.75) | ORAI1TRPC3TRPC5CRACR2ATP53 | |
| SCHEMBL12327571 | 0.85 | ORAI1 (0.74) | ORAI1TRPC3TRPC5CRACR2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312336-A1 | Compositions And Methods For Treating Cancer With Calcium Channel Inhibitors | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-12365945-B2 | Urinary microbiomic profiling | Convergent Genomics, Inc. (US) | 2025-07-22 | — | — | US | claimed |
| US-20250073202-A1 | METHODS TO TREAT RENAL DISORDERS USING CALCIUM CHANNEL INHIBITORS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-03-06 | — | — | US | claimed |
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | UNIVERSITY OF NOTRE DAME DU LAC | 2025-01-09 | — | — | US | claimed |
| CN-119082116-A | DBN1 gene, inhibitor and application thereof | 上海交通大学 | 2024-12-06 | — | — | CN | claimed |
| US-20230414609-A1 | USES OF ORAI1-SPECIFIC CALCIUM CHANNELS IN TREATMENT OF ORAL CANCER | NEW YORK UNIVERSITY | 2023-12-28 | — | — | US | claimed |
| CN-112255364-B | Soft measurement method for real-time quantitative determination of sintering end point state | 唐山学院 | 2022-07-01 | — | — | CN | claimed |
| WO-2022047234-A1 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | WO | claimed |
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | claimed |
| US-20170202932-A1 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2017-07-20 | — | — | US | claimed |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | claimed |
| US-20150190366-A1 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2015-07-09 | — | — | US | claimed |
| CN-122036742-A | Small molecular compound and application thereof | 澳门科技大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12613603-B2 | Display device | SAMSUNG DISPLAY CO., LTD. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12613596-B2 | Display device | SAMSUNG DISPLAY CO., LTD. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20260112967-A1 | CHARGE PUMP FOR GATE DRIVER CIRCUIT | TEXAS INSTRUMENTS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20040184995-A1 | Novel dry powder inhalation for lung-delivery and manufacturing method thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-6506747-B1 | Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | disclosed |
| WO-1999062885-A1 | SUBSTITUTED 1-(4-AMINOPHENYL)PYRAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | MGAM, OPRM1, BPGM | ORAI1 226/4885TRPC3 3702/4885TRPC5 3232/4885 |
| US-12613596-B2 | Display device | EPHA8, NCS1, EPHA4 | ORAI1 495/4885TRPC3 1930/4885TRPC5 2117/4885 |
| US-20260112967-A1 | CHARGE PUMP FOR GATE DRIVER CIRCUIT | HCN1, CDC25A, CDC25B | ORAI1 19/4885TRPC3 2169/4885TRPC5 779/4885 |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, EIF2AK2 | ORAI1 3769/4885TRPC3 2752/4885TRPC5 2959/4885 |
| US-12613603-B2 | Display device | EPHA8, EPHA4, NCS1 | ORAI1 1394/4885TRPC3 984/4885TRPC5 1189/4885 |
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | IL5, IL2, IL4 | ORAI1 3522/4885TRPC3 4362/4885TRPC5 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.